Clinical Trial Search

Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine

Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants

Primary: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP) — 72.1; 67.4 ng/mL — p=0.53

Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants

Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL

Primary: Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude — 0.1796; 0.1507; -0.3872; 0.3731…

Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023

Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…

Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…

Primary: Percent Change in Serum Myostatin Levels From Pre- to 3 Hours Post-exercise — -6.9; 8.5 % change in serum myostatin — p=0.303

Primary: Resting Energy Expenditure at Low Temperature — 1.277; 1.134; 1.300; 1.271 kcal/min

Primary: Lean Mass — 403 grams

Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL

Primary: Change From Baseline to End of Treatment (EOT) in 24-hour Average Systolic Blood Pressure (SBP) — 1.9 mmHg

Primary: Sexual Pleasure Scale Score for Fitted Versus Standard Condoms — 71.52; 70.13 score on a scale — p=<0.05

Primary: Change From Baseline in 24-hour Average Systolic Blood Pressure (SBP) Obtained at Week 16 — 123.2; 3.5 millimeters of mercury (mmHg)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants

Primary: Maximum Observed Concentration (Cmax) of Ritlecitinib: MR Capsules vs Oral Solution Under Fasted Condition — 671.6; 145.1; 84.96 Nanogram per milliliter (ng/mL)

Primary: Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA) — 0.14; 0.74; 4.43; 4.13 kg

Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose

Primary: Percent of Participants Correctly Determining Eligibility for Use of the Device (Responders) — 94 percentage of participants

Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change

Primary: Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS) — 2.77; 2.78; 2.15 millimeters of mercury (mmHg)

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Proportion of Suppressors After Dexamethasone — 0; 1 Participants — p=0.4872

Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter

Primary: Condomless Anal Intercourse or Condomless Vaginal Intercourse — 49; 50 Participants — p=0.94

Primary: Estimate Cardiovascular Efficiency After Aerobic Exercise — 24.01; 31.2; 32.3 ml/kg(min) — p=.001

Primary: Fasting Insulin — 10.26; 10.39 uIU/ml